{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T13:08:33Z","timestamp":1786799313326,"version":"build-2736575974"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Mega-project for Innovative Drugs","award":["2019ZX09721001-006-004"],"award-info":[{"award-number":["2019ZX09721001-006-004"]}]},{"name":"CHINET Antimicrobial Surveillance Network","award":["2018QD099 and 2018QD100"],"award-info":[{"award-number":["2018QD099 and 2018QD100"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s10096-021-04278-3","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T07:10:20Z","timestamp":1621494620000},"page":"2271-2283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparative activities of sitafloxacin against recent clinical isolates in hospitals across China"],"prefix":"10.1007","volume":"40","author":[{"given":"Shi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renru","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4493-0619","authenticated-orcid":false,"given":"Fupin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"4278_CR1","doi-asserted-by":"publisher","first-page":"ofz108","DOI":"10.1093\/ofid\/ofz108","volume":"6","author":"T Asakura","year":"2019","unstructured":"Asakura T, Suzuki S, Fukano H et al (2019) Sitafloxacin-containing regimen for the treatment of refractory Mycobacterium avium complex lung disease. Open Forum Infect Dis 6:ofz108","journal-title":"Open Forum Infect Dis"},{"key":"4278_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s40064-016-2044-5","volume":"5","author":"W Manosuthi","year":"2016","unstructured":"Manosuthi W, Wiboonchutikul S (2016) Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis. Springerplus 5:410","journal-title":"Springerplus"},{"key":"4278_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2165\/11207380-000000000-00000","volume":"71","author":"GM Keating","year":"2011","unstructured":"Keating GM (2011) Sitafloxacin: in bacterial infections. Drugs 71:731\u2013744","journal-title":"Drugs"},{"key":"4278_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1089\/mdr.2017.0054","volume":"24","author":"R Hamasuna","year":"2018","unstructured":"Hamasuna R, Ohnishi M, Matsumoto M et al (2018) In Vitro activity of sitafloxacin and additional newer generation fluoroquinolones against ciprofloxacin-resistant Neisseria gonorrhoeae isolates. Microb Drug Resist 24:30\u201334","journal-title":"Microb Drug Resist"},{"key":"4278_CR5","first-page":"469","volume":"100","author":"W Tantisiriwat","year":"2017","unstructured":"Tantisiriwat W, Linasmita P (2017) In vitro activity of sitafloxacin and other antibiotics against bacterial isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital. J Med Assoc Thail 100:469\u2013478","journal-title":"J Med Assoc Thail"},{"key":"4278_CR6","first-page":"3485","volume":"16","author":"N Xu","year":"2018","unstructured":"Xu N, Wang G, Leng Y et al (2018) Sulbactam enhances the in vitro activity of sitafloxacin against extensively-drug resistant Acinetobacter baumannii. ExpTher Med 16:3485\u20133491","journal-title":"ExpTher Med"},{"key":"4278_CR7","unstructured":"Clinical and Laboratory Standards Institute (2020) Performance standards for antimicrobial susceptibility testing; M100 30th. Clin Lab Stand Instit"},{"key":"4278_CR8","volume-title":"M07, 11th Ed. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"CLSI","year":"2018","unstructured":"CLSI (2018) M07, 11th Ed. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Clinical and Laboratory Standards Institute, Wayne"},{"key":"4278_CR9","volume-title":"Methods for antimicrobial susceptibility testing for human mycoplasmas; approved guideline (M43-A)","author":"CLSI","year":"2011","unstructured":"CLSI (2011) Methods for antimicrobial susceptibility testing for human mycoplasmas; approved guideline (M43-A). Clinical and Laboratory Standards Institute, Wayne"},{"key":"4278_CR10","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s10096-019-03673-1","volume":"38","author":"F Hu","year":"2019","unstructured":"Hu F, Guo Y, Yang Y et al (2019) Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis 38:2275\u20132281","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4278_CR11","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1128\/AAC.44.4.1102-1107.2000","volume":"44","author":"D Milatovic","year":"2000","unstructured":"Milatovic D, Schmitz FJ, Brisse S, Verhoef J, Fluit AC (2000) In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob Agents Chemother 44:1102\u20131107","journal-title":"Antimicrob Agents Chemother"},{"key":"4278_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/jac\/46.1.109","volume":"46","author":"FJ Schmitz","year":"2000","unstructured":"Schmitz FJ, Fluit AC, Milatovic D et al (2000) In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 46:109\u2013113","journal-title":"J Antimicrob Chemother"},{"key":"4278_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/ja.2013.17","volume":"66","author":"A Amano","year":"2013","unstructured":"Amano A, Matsuzaki K, Kishi N et al (2013) In vitro activity of sitafloxacin against clinical isolates in 2012. Jpn J Antibiot 66:311\u2013330 [Japanese]","journal-title":"Jpn J Antibiot"},{"key":"4278_CR14","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1128\/AAC.45.6.1721-1729.2001","volume":"45","author":"GV Doern","year":"2001","unstructured":"Doern GV, Heilmann KP, Huynh HK et al (2001) Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 45:1721\u20131729","journal-title":"Antimicrob Agents Chemother"},{"key":"4278_CR15","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1128\/AAC.46.10.3276-3279.2002","volume":"46","author":"DR Snydman","year":"2002","unstructured":"Snydman DR, Jacobus NV, McDermott LA et al (2002) In vitro activities of newer quinolones against Bacteroides group organisms [Errata in Antimicrob Agents Chemother 2003;47(2):831]. Antimicrob Agents Chemother 46:3276\u20133279","journal-title":"Antimicrob Agents Chemother"},{"key":"4278_CR16","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s10156-013-0580-2","volume":"19","author":"Y Tanigawara","year":"2013","unstructured":"Tanigawara Y, Kaku M, Totsuka K, Tsuge H, Saito A (2013) Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections. J Infect Chemother 19:858\u2013866","journal-title":"J Infect Chemother"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-021-04278-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-021-04278-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-021-04278-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T20:01:26Z","timestamp":1634414486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-021-04278-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["4278"],"URL":"https:\/\/doi.org\/10.1007\/s10096-021-04278-3","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]},"assertion":[{"value":"27 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Huashan Hospital, Fudan University (number: 2019-572).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}